Department of Neurology, University of Minnesota, Minneapolis, MN 55455, USA.
J Clin Pharm Ther. 2013 Apr;38(2):175-6. doi: 10.1111/jcpt.12031. Epub 2012 Dec 4.
Posterior reversible encephalopathy syndrome (PRES) can be the result of acute hypertension, eclampsia, renal failure and the use of immunosuppressive or cytotoxic agents. We report a case of PRES as a result of the use of pazopanib, a vascular endothelial growth factor inhibitor used for renal cell carcinoma (RCC).
A 76-year-old man treated with RCC develops PRES shortly after the initiation of pazopanib.
There are no known reports of the association between PRES and pazopanib. We postulate that pazopanib can disrupt the normal endothelial function of the brain leading to the development of PRES.
后部可逆性脑病综合征（PRES）可能是急性高血压、子痫、肾衰竭和使用免疫抑制或细胞毒性药物的结果。我们报告了一例由于使用血管内皮生长因子抑制剂帕唑帕尼（用于治疗肾细胞癌）而导致 PRES 的病例。
一名 76 岁男性患有肾细胞癌，在开始使用帕唑帕尼后不久出现 PRES。
目前尚无 PRES 与帕唑帕尼相关的报道。我们推测帕唑帕尼可能会破坏大脑的正常内皮功能，从而导致 PRES 的发生。
